Clinical Trial Update: Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating the tolerability, steady-state pharmacokinetics, and erythrocyte COMT inhibition of BIA 3-202 in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED